

## **Modus announces outcome of exercise of warrants of series TO 2026 and receives approximately SEK 9.5 million**

**Modus Therapeutics Holding AB (publ) (“Modus” or the “Company”) today announces the outcome of the exercise of warrants of series TO 2026, which were issued in connection with the rights issue carried out in the summer of 2025. The exercise rate for the warrants of series TO 2026 amounted to 94.8 percent, and the Company will receive approximately SEK 9.5 million before transaction costs.**

Of the total 28,563,198 warrants of series TO 2026 issued, 27,073,298 warrants were exercised for subscription of 27,073,298 new shares in the Company at a subscription price of SEK 0.35 per share, corresponding to an exercise rate of 94.8 percent. Through the exercise of the warrants, the Company receives approximately SEK 9.5 million before transaction costs.

### **Number of shares, share capital and dilution**

Through the exercise of warrants of series TO 2026, the number of shares in the Company increases by 27,073,298 and the share capital increases by SEK 1,624,397.88, from SEK 7,297,709.58 to SEK 8,922,107.46, corresponding to a dilution of approximately 18 percent calculated on the number of shares after exercise.

### **Issuing agent**

Bergs Securities AB acts as issuing agent.

### **This Information**

This information was submitted for publication, through the agency of the contact persons below, on 27 April 2026 at 22:15 CEST.

### **For more information on Modus Therapeutics, please contact:**

John Öhd, CEO, Modus Therapeutics

Phone: +46 (0) 70 766 80 97

Email: [john.ohd@modustx.com](mailto:john.ohd@modustx.com)

### **Certified Adviser**

Bergs Securities AB

Hemsida: [www.bergssecurities.se](http://www.bergssecurities.se)

**About Modus Therapeutics and sevuparin**

Modus is a Swedish biotech company developing its patented polysaccharide, sevuparin, as a treatment option for several major unmet medical needs, including anemia in kidney disease and other chronic inflammatory conditions, severe malaria, sepsis, and other disorders involving severe systemic inflammation. There is a great need for new treatments that can effectively treat these conditions. Modus' ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market ("MODTX"). More information is available at [www.modustx.com](http://www.modustx.com).

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

**Attachments**

**Modus announces outcome of exercise of warrants of series TO 2026 and receives approximately SEK 9.5 million**